Brief: Vectivbio Announces First Two Patients Dosed In Phase 2 Stargaze Study Of Apraglutide For The Treatment Of Acute Graft-Versus-Host Disease
02/06/2022 13:16
June 2 (Reuters) - VectivBio Holding AG VECT.O :
* VECTIVBIO ANNOUNCES FIRST TWO PATIENTS DOSED IN PHASE 2
STARGAZE
STUDY OF APRAGLUTIDE FOR THE TREATMENT OF ACUTE
GRAFT-VERSUS-HOST DISEASE
* VECTIVBIO HOLDING AG - INTERIM PROOF-OF-CONCEPT DATA
ANTICIPATED
FROM STARGAZE IN H1 2023
Source text for Eikon: ID:nGNX9cjK3K
Further company coverage: VECT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VectivBio Holding AG
See all newsBrief: Ironwood And VectivBio Announce Expiration Of Hart-Scott-Rodino Waiting Period For Proposed Acquisition Of VectivBio
Brief: Ironwood Pharmaceuticals Says If Deal Aborts, VectivBio To Pay Termination Fee
U.S. STOCKS ON THE MOVE-Pfizer, Zoom Video, American Airlines
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
U.S. STOCKS ON THE MOVE-NuScale Power Corp, Foot Locker, Greenhill